FREQUENT BASELINE EGFR MUTATION T790M IN CYTOLOGICAL SPECIMENS OF TYROSINE KINASE INHIBITOR (TKI) NAIVE ADENOCARCINOMA NSCLC PATIENTS

被引：0
|
作者：
Andarini, S. L. [1 ]
Zaini, J. [1 ]
Hudoyo, A. [1 ]
Hidayat, H. [1 ]
Widjajahakim, G. [2 ]
Utomo, A. R. [3 ]
机构：
[1] Univ Indonesia, Persahabatan Hosp, Dept Pulmonol & Resp Med, Fac Med, Jakarta, Indonesia
[2] KalGen Lab, Pathol Core Facil, Jakarta, Indonesia
[3] KalGen Lab, Stem Cell & Canc Inst, Canc Diagnost Res, Jakarta, Indonesia
来源：
RESPIROLOGY | 2016年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
APSR6-0587
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [1] Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naive EGFR-Mutant Lung Adenocarcinomas
    Cabanero, M.
    Kuo, J.
    Liu, N.
    Tsao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S443 - S443
  • [2] High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact?
    Ye, Xin
    Zhu, Zhong-Zheng
    Zhong, Lei
    Lu, Yachao
    Sun, Yun
    Yin, Xiaolu
    Yang, Zhenfan
    Zhu, Guanshan
    Ji, Qunsheng
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (09) : 1118 - 1120
  • [3] High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: Truth or artifact?.
    Ye, Xin
    Zhu, Zhong-zheng
    Zhong, Lei
    Lu, Yachao
    Sun, Yun
    Yin, Xiaolu
    Yang, Zhenfan
    Zhu, Guanshan
    Ji, Qunsheng
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [4] T790M Mutation Detection, Clinical Characteristics and Impact in NSCLC Patients Treated with EGFR Tyrosine Kinase Inhibitors
    Bei, L.
    Oliveira, J.
    Pinheiro, M.
    Veiga, I.
    Peixoto, A.
    Rocha, P.
    Oliveira, C.
    Rodrigues, A.
    Pousa, I.
    Azevedo, I.
    Henrique, R.
    Teixeira, M.
    Soares, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2220 - S2221
  • [5] Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
    Lee, Sang Hoon
    Kim, Eun Young
    Kim, Arum
    Chang, Yoon Soo
    CANCER BIOLOGY & THERAPY, 2020, 21 (08) : 741 - 748
  • [6] Efficacy of YK-029A, a novel EGFR TKI, in advanced NSCLC patients with acquired T790M mutation
    Wan, Rui
    Chau, Yi Fung
    Zhao, Jun
    Liu, Zhe
    Zhao, Mingfang
    Zhao, Yanqiu
    Dai, Xiumei
    Pan, Yueyin
    Zhang, Zhihong
    Yao, Yu
    Yang, Kunyu
    Wu, Lin
    Xie, Yanyan
    Chen, Bi
    Yang, Yixuan
    Guo, Yongqi
    Wang, Jie
    Duan, Jianchun
    CANCER RESEARCH, 2024, 84 (07)
  • [7] Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Choi, Yoon-La
    Ahn, Jin Seok
    Park, Keunchil
    LUNG CANCER, 2013, 82 (02) : 294 - 298
  • [8] Characterization of T790M According to Primary EGFR Mutation in Post EGFR-TKI Progression NSCLC in Brazil
    Ferreira, C.
    Zalis, M.
    Custodio, M.
    Montenegro, G.
    Zukin, M.
    Mathias, C.
    Haddad, C.
    Mascarenhas, E.
    Araujo, L.
    Montella, T.
    Da Silva, B.
    Bustamante, C.
    Muras, A.
    Reis, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S158 - S158
  • [9] REVERSAL OF RESISTANCE OF EGFR TYROSINE KINASE INHIBITOR (GEFITINIB) BY EGFR T790M SPECIFIC siRNA
    Lee, C-T.
    Park, M-Y.
    Eo, E. Y.
    Lee, J. H.
    ANNALS OF ONCOLOGY, 2013, 24 : 19 - 20
  • [10] Epithelial Mesenchymal Transition in TKI Resistant NSCLC with T790M Mutation
    Iderzorig, Tsatsral
    Chhabra, Gagan
    Puri, Neelu
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S286 - S286
12345